MIR100HG overexpression was associated with cetuximab resistance and poor prognosis in colorectal and cervical cancer patients, and it was found to promote cell proliferation in laryngeal squamous cell carcinomas, hepatocellular carcinomas, osteosarcomas, and triple-negative breast cancer [53, 54, 55, 56, 57, 58, 59, 60]. This evidence concerns the gene MIR100HG and hepatocellular carcinoma.